Imakrebin

Imatinib, the active ingredient in Imakrebin, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It treats chronic myeloid leukemia, Philadelphia chromosome‑positive acute lymphoblastic leukemia, and gastrointestinal stromal tumor in adult patients. It is used as a targeted therapy in adult patients with these malignancies, improving survival outcomes when prescribed by qualified clinicians.

GNH USA supplies Imakrebin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, with distribution networks across Europe, Asia and the Americas.

Imakrebin is a tyrosine kinase inhibitor used in the treatment of specific hematologic and solid‑tumor cancers. - Chronic myeloid leukemia (CML): reduces leukemic cell proliferation and improves long‑term survival. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): induces remission by targeting BCR‑ABL driven blasts. - Gastrointestinal stromal tumor (GIST): inhibits KIT‑driven tumor growth, leading to disease control.

Imakrebin may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Diarrhea: increased bowel movements. - Edema: swelling of hands, feet or ankles. - Fatigue: feeling unusually tired. - Muscle cramps: involuntary tightening of muscles. - Rash: skin irritation or redness.

Serious or Rare Side Effects: - Severe neutropenia: dangerously low white‑blood‑cell count. - Hepatotoxicity: liver enzyme elevations or liver injury. - Cardiac dysfunction: reduced heart pumping ability. - Pulmonary arterial hypertension: high blood pressure in lung arteries. - Hemorrhage: abnormal bleeding or bruising.

Before initiating therapy, clinicians should evaluate baseline health parameters and monitor patients regularly. - Blood count monitoring: check complete blood count frequently to detect cytopenias. - Liver function assessment: perform baseline and periodic liver enzyme tests. - Cardiac evaluation: assess ejection fraction in patients with pre‑existing heart disease. - Hypersensitivity avoidance: discontinue if severe allergic reaction occurs. - Pregnancy considerations: use only if potential benefit justifies potential risk, as safety data are limited. - Store at room temperature: keep in the original pack, protect from moisture.

Imakrebin can interact with several medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase imatinib exposure and toxicity. - Antacids containing aluminum or magnesium: can reduce absorption of imatinib. - Warfarin: concurrent use may enhance anticoagulant effect and bleeding risk.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower imatinib levels, reducing efficacy. - Diuretics: may exacerbate fluid retention. - QT‑prolonging agents: combined use can increase risk of cardiac arrhythmias.